Rapid Dose Therapeutics Profit Margin

The latest profit margin for DOSE.CN is -148.27% as of August 2026. That compares with -174.99% in the prior-year period — up 15.3% year over year. That is below the Healthcare sector average of 9.48%. Investors often review this figure alongside Rapid Dose Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, DOSE.CN's profit margin moved from -174.99% to -148.27% — a 15.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Rapid Dose Therapeutics's valuation or profitability profile.

Against Healthcare companies, DOSE.CN currently prints -148.27% for profit margin, while the sector average sits near 9.48%. That is roughly 1663.9% below the sector mean. Large gaps often invite a closer look at Rapid Dose Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Rapid Dose Therapeutics converts resources into returns. At -148.27%, DOSE.CN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -174.99% in the prior-year period — up 15.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting DOSE.CN's profit margin (-148.27%), review year-over-year change from -174.99%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.